Safety and efficacy of nilotinib in adult patients with chronic myeloid leukemia: a post-marketing surveillance study in Korea
Seo-Yeon AHN; Sang-Kyun SON; Gyu-Hyung LEE; Inho KIM; June-Won CHEONG; Won-Sik LEE; Byung-Soo KIM; Deog-Yeon JO; Chul-Won JUNG; Chu-Myoung SEONG; Jae-Hoon LEE; Young-Jin YUH; Min-Kyoung KIM; Hun-Mo RYOO; Moo-Rim PARK; Su-Hee CHO; Hoon-Gu KIM; Dae-Young ZANG; Jinny PARK; Hawk KIM; Seryeon LEE; Sung-Hyun KIM; Myung-Hee CHANG; Ho-Sup LEE; Chul-Won CHOI; Jihyun KWON; Sung-Nam LIM; Suk-Joong OH; Inkyung JOO; Dong-Wook KIM.
Blood Research
; : 144-151, 2022.
Artículo
en Inglés
| WPRIM | ID: wpr-937245
Background@#Nilotinib is a tyrosine kinase inhibitor approved by the Ministry of Food and Drug Safety for frontline and 2nd line treatment of Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML). This study aimed to confirm the safety and efficacy of nilotinib in routine clinical practice within South Korea. @*Methods@#An open-label, multicenter, single-arm, 12-week observational post-marketing surveillance (PMS) study was conducted on 669 Korean adult patients with Ph + CML from December 24, 2010, to December 23, 2016. The patients received nilotinib treatment in routine clinical practice settings. Safety was evaluated by all types of adverse events (AEs) during the study period, and efficacy was evaluated by the complete hematological response (CHR) and cytogenetic response. @*Results@#During the study period, AEs occurred in 61.3% (410 patients, 973 events), adverse drug reactions (ADRs) in 40.5% (271/669 patients, 559 events), serious AEs in 4.5% (30 patients, 37 events), and serious ADRs in 0.7% (5 patients, 8 events). Furthermore, unexpected AEs occurred at a rate of 6.9% (46 patients, 55 events) and unexpected ADRs at 1.2% (8 patients, 8 events). As for the efficacy results, CHR was achieved in 89.5% (442/494 patients), and minor cytogenetic response or major cytogenetic response was achieved in 85.8% (139/162 patients). @*Conclusion@#This PMS study shows consistent results in terms of safety and efficacy compared with previous studies. Nilotinib was well tolerated and efficacious in adult Korean patients with Ph + CML in routine clinical practice settings.
Biblioteca responsable:
WPRO
Texto completo
Documentos relacionados